Abstract: Disclosed herein are methods for assaying a potential drug candidate for the treatment, prevention, reduction or amelioration of neurodegenerative diseases and disorders. Some aspects pertain to stimulating a cell to induce a phenotype characteristic of a neurodegenerative disease or disorder and contacting the cell with a potential drug candidate and determining a responsive change, wherein a decrease or loss in the phenotype is indicative that the drug candidate is capable of treating, preventing, reducing or ameliorating neurodegenerative diseases or disorders.

Abstract: Disclosed herein are compositions and methods useful for the treatment or amelioration of various diseases, disorders, or conditions. Some aspects pertain to a pharmaceutical composition comprising 17-ethynyl-10R, 13S dimethyl 2, 3, 4, 7, 8R, 9S, 10, 11, 12, 13, 14S, 15, 16, 17-hexadecahydro-1H-cyclopenta[a]phenanthrene-3R, 7R, 17S-triol, including solid states thereof. Also presented herein is the surprising discovery that exposing a subject to the compositions disclosed herein can treat, reduce, or ameliorate a condition related to biological clocks.

Abstract: Disclosed herein are compositions and methods useful for the treatment or amelioration of various diseases, disorders, or conditions. Some aspects pertain to a pharmaceutical composition comprising 17-ethynyl-10R, 13S-dimethyl 2, 3, 4, 7, 8R, 9S, 10, 11, 12, 13, 14S, 15, 16, 17-hexadecahydro-1H-cyclopenta[a]phenanthrene-3R, 7R, 17S-triol, including solid states thereof. Also presented herein is the surprising discovery that exposing a subject to the compositions disclosed herein can treat, reduce, or ameliorate symptoms of a neurodegenerative condition.

Abstract: Disclosed herein is a pharmaceutical composition comprising solid state forms of 17-ethynyl-10R, 13S-dimethyl 2, 3, 4, 7, 8R, 9S, 10, 11, 12, 13, 14S, 15, 16, 17-hexadecahydro-1H-cyclopenta[a]phenanthrene-3R, 7R, 17S-triol. Also disclosed herein is a method for using the solid state forms for the treatment of conditions related to neurodegenerative conditions including Parkinson's disease.

Abstract: The invention relates to methods to use 17?-ethynylandrost-5-ene-3?,7?,17?-triol to treat ocular diseases or conditions such as dry eye, uveitis or retinitis. The compound can be administered topically to the eye, by intravitreal injection or systemically, e.g., orally.

Abstract: The invention provides 17?-ethynylandrost-5-ene-3?,7?,17?-triol for use in methods to treat, e.g., pre-diabetic hyperglycemia or type 2 diabetes patients having a fasting blood glucose level of at least 110 mg/dL or a post prandial glucose level of at least about 140 mg/dL an optionally a body mass index of >29.9, wherein the patients are not concurrently treated with metformin and optionally another antidiabetic agent. In these methods, the patient will preferably have a fasting insulin level of at least 3.5 to 4 ?U/mL.

Abstract: The invention provides 17?-ethynylandrost-5-ene-3?, 7?, 17?-triol for use in methods to treat, e.g., hyperglycemia or diabetes patients having a body mass index of at least about 31 (?30.5, ?31 or ?32), wherein the patients are not concurrently treated with metformin and optionally another antidiabetic agent. In these methods, the patient will generally have a fasting insulin level of at least 4 ?U/mL or another characteristic as described herein.

Abstract: The invention provides compositions comprising formula 1 steroids, e.g., 16?-bromo-3?-hydroxy-5?-androstan-17-one hemihydrate and one or more excipients, typically wherein the composition comprises less than about 3% water. The compositions are useful to make improved pharmaceutical formulations. The invention also provides methods of intermittent dosing of steroid compounds such as analogs of 16?-bromo-3?-hydroxy-5?-androstan-17-one and compositions useful in such dosing regimens. The invention further provides compositions and methods to inhibit pathogen (viral) replication, ameliorate symptoms associated with immune dysregulation and to modulate immune responses in a subject using certain steroids and steroid analogs. The invention also provides methods to make and use these immunomodulatory compositions and formulations.

Abstract: The invention provides, inter alia, methods to treat, e.g., hyperglycemia or diabetes patients having two or more of a BMI of at least 28 or 29, a fasting insulin level of at least 4 ?U/mL or at least 6 ?U/mL and optionally (i) a serum MCP1 level of at least about 400 pg/mL or at least about 500 pg/mL. The treatment method includes administering 17?-ethynylandrost-5-ene-3?, 7?, 17?-triol and optionally another compound such as metformin or glyburide. Specific embodiments include use of 17?-ethynylandrost-5-ene-3?, 7?, 17?-triol for the treatment of hypercholesterolemia in a patient and a BMI of at least 28 or 29 and optionally hyperglycemia. In these embodiments, the patient will most preferably have a fasting insulin level of at least 4 ?U/mL or at least 5 ?U/mL.

Abstract: The invention provides compositions comprising formula 1 steroids, e.g., 16?-bromo-3?-hydroxy-5?-androstan-17-one hemihydrate and one or more excipients, typically wherein the composition comprises less than about 3% water. The compositions are useful to make improved pharmaceutical formulations. The invention also provides methods of intermittent dosing of steroid compounds such as analogs of 16?-bromo-3?-hydroxy-5?-androstan-17-one and compositions useful in such dosing regimens. The invention further provides compositions and methods to inhibit pathogen (viral) replication, ameliorate symptoms associated with immune dysregulation and to modulate immune responses in a subject using certain steroids and steroid analogs. The invention also provides methods to make and use these immunomodulatory compositions and formulations.

Abstract: The invention relates to the use of compounds to ameliorate or treat a condition such as a cystic fibrosis, neutropenia or other exemplified conditions. Exemplary compounds that can be used include 3?-hydroxy-17?-aminoandrost-5-ene, 3?-hydroxy-16?-fluoro-17?-aminoandrost-5-ene, 3?-hydroxy-16?-fluoro-17?-aminoandrost-5-ene, 3?-hydroxy-16?-fluoro-17?-aminoandrost-5-ene, 1?,3?-dihydroxy-4?-fluoroandrost-5-ene-17-one, 1?,3?,17?-trihydroxy-4?-fluoroandrost-5-ene, 1?,3?-dihydroxy-6?-bromoandrost-5-ene, 1?-fluoro-3?,12?-dihydroxyandrost-5-ene-17-one, 1?-fluoro-3?,4?-dihydroxyandrost-5-ene and 4?-fluoro-3?,6?,17?-trihydroxyandrostane.

Abstract: The invention relates to solid state forms of androst-5-ene-3?,7?,16?,17?-triol, formulations containing or prepared from such solid state forms and use of such materials for modulating acute and chronic non-productive inflammation. The formulations can be used to prevent, treat or slow the progression of conditions related to autoimmunity such as arthritis, multiple sclerosis, ulcerative colitis or Type 1 diabetes. The formulations can also be used to prevent, treat or slow the progression of conditions related to metabolic disorders such as Type 2 diabetes.

Abstract: The invention provides compositions comprising formula 1 steroids, e.g., 16?-bromo-3?-hydroxy-5?-androstan-17-one hemihydrate and one or more excipients, typically wherein the composition comprises less than about 3% water. The compositions are useful to make improved pharmaceutical formulations. The invention also provides methods of intermittent dosing of steroid compounds such as analogs of 16?-bromo-3?-hydroxy-5?-androstan-17-one and compositions useful in such dosing regimens. The invention further provides compositions and methods to inhibit pathogen (viral) replication, ameliorate symptoms associated with immune dysregulation and to modulate immune responses in a subject using certain steroids and steroid analogs. The invention also provides methods to make and use these immunomodulatory compositions and formulations.

Abstract: The invention relates to the use of compounds to ameliorate or treat an condition such as a cystic fibrosis, neutropenia or other exemplified conditions. Exemplary compounds that can be used include 3?-hydroxy-17?-aminoandrost-5-ene, 3?-hydroxy-16?-fluoro-17?-aminoandrost-5-ene, 3?-hydroxy-16?-fluoro-17?-aminoandrost-5-ene, 3?-hydroxy-16?-fluoro-17?-aminoandrost-5-ene, 1?,3?-dihydroxy-4?-fluoroandrost-5-ene-17-one, 1?,3?,17?-trihydroxy-4?-fluoroandrost-5-ene, 1?,3?-dihydroxy-6?-bromoandrost-5-ene, 1?-fluoro-3?,12?-dihydroxyandrost-5-ene-17-one, 1?-fluoro-3?,4?-dihydroxyandrost-5-ene and 4?-fluoro-3?,6?,17?-trihydroxyandrostane.

Abstract: The invention relates to the use of compounds to ameliorate or treat a condition such as a cystic fibrosis, neutropenia or other exemplified conditions. Exemplary compounds that can be used include 3?-hydroxy-17?-aminoandrost-5-ene, 3?-hydroxy-16?-fluoro-17?-aminoandrost-5-ene, 3?-hydroxy-16?-fluoro-17?-aminoandrost-5-ene, 3?-hydroxy-16?-fluoro-17?-aminoandrost-5-ene, 1?,3?-dihydroxy-4?-fluoroandrost-5-ene-17-one, 1?,3?,17?-trihydroxy-4?-fluoroandrost-5-ene, 1?,3?-dihydroxy-6?-bromoandrost-5-ene, 1?-fluoro-3?,12?-dihydroxyandrost-5-ene-17-one, 1?-fluoro-3?,4?-dihydroxyandrost-5-ene and 4?-fluoro-3?,6?, 17?-trihydroxyandrostane.

Abstract: The invention provides compositions comprising formula 1 steroids, e.g., 16&agr;-bromo-3&bgr;-hydroxy-5&agr;-androstan-17-one hemihydrate and one or more excipients, typically wherein the composition comprises less than about 3% water. The compositions are useful to make improved pharmaceutical formulations. The invention also provides methods of intermittent dosing of steroid compounds such as analogs of 16&agr;-bromo-3&bgr;-hydroxy-5&agr;-androstan-17-one and compositions useful in such dosing regimens. The invention further provides compositions and methods to inhibit pathogen (viral) replication, ameliorate symptoms associated with immune dysregulation and to modulate immune responses in a subject using certain steroids and steroid analogs. The invention also provides methods to make and use these immunomodulatory compositions and formulations.

Abstract: The invention provides compositions comprising formula 1 steroids, e.g., 16&agr;-bromo-3&bgr;-hydroxy-5&agr;-androstan-17-one hemihydrate and one or more excipients, typically wherein the composition comprises less than about 3% water. The compositions are useful to make improved pharmaceutical formulations. The invention also provides methods of intermittent dosing of steroid compounds such as analogs of 16&agr;-bromo-3&bgr;-hydroxy-5&agr;-androstan-17-one and compositions useful in such dosing regimens. The invention further provides compositions and methods to inhibit pathogen (viral) replication, ameliorate symptoms associated with immune dysregulation and to modulate immune responses in a subject using certain steroids and steroid analogs. The invention also provides methods to make and use these immunomodulatory compositions and formulations.

Abstract: The invention relates to the use of compounds to ameliorate or treat an condition such as a cystic fibrosis, neutropenia or other exemplified conditions. Exemplary compounds that can be used include 3&bgr;-hydroxy-17&bgr;-aminoandrost-5-ene, 3&bgr;-hydroxy-16&agr;-fluoro-17&bgr;-aminoandrost-5-ene, 3&agr;-hydroxy-16&agr;-fluoro-17&bgr;-aminoandrost-5-ene, 3&bgr;-hydroxy-16&bgr;-fluoro-17&bgr;-aminoandrost-5-ene, 1&agr;,3&bgr;-dihydroxy-4&agr;-fluoroandrost-5-ene-17-one, 1&agr;,3&bgr;,17&bgr;-trihydroxy-4&agr;-fluoroandrost-5-ene, 1&bgr;,3&bgr;-dihydroxy-6&agr;-bromoandrost-5-ene, 1&agr;-fluoro-3&bgr;,12&agr;-dihydroxyandrost-5-ene-17-one, 1&agr;-fluoro-3&bgr;,4&agr;-dihydroxyandrost-5-ene and 4&agr;-fluoro-3&bgr;,6&agr;,17&bgr;-trihydroxyandrostane.

Abstract: The invention provides compositions comprising formula 1 steroids, e.g., 16&agr;-bromo-3&bgr;-hydroxy-5&agr;-androstan-17-one hemihydrate and one or more excipients, typically wherein the composition comprises less than about 3% water. The compositions are useful to make improved pharmaceutical formulations. The invention also provides methods of intermittent dosing of steroid compounds such as analogs of 16&agr;-bromo-3&bgr;-hydroxy-5&agr;-androstan-17-one and compositions useful in such dosing regimens. The invention further provides compositions and methods to inhibit pathogen (viral) replication, ameliorate symptoms associated with immune dysregulation and to modulate immune responses in a subject using certain steroids and steroid analogs. The invention also provides methods to make and use these immunomodulatory compositions and formulations.

Abstract: The invention provides compositions comprising formula 1 steroids, e.g., 16&agr;-bromo-3&bgr;-hydroxy-5&agr;-androstan-17-one hemihydrate and one or more excipients, typically wherein the composition comprises less than about 3% water. The compositions are useful to make improved pharmaceutical formulations. The invention also provides methods of intermittent dosing of steroid compounds such as analogs of 16&agr;-bromo-3&bgr;-hydroxy-5&agr;-androstan-17-one and compositions useful in such dosing regimens. The invention further provides compositions and methods to inhibit pathogen (viral) replication, ameliorate symptoms associated with immune dysregulation and to modulate immune responses in a subject using certain steroids and steroid analogs. The invention also provides methods to make and use these immunomodulatory compositions and formulations.